Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Pipeline Review, H1 2018
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Pipeline Review, H1 2018
SUMMARY
According to the recently published report 'Galectin 1 - Pipeline Review, H1 2018'; Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Galectin-1 is a protein encoded by the LGALS1 gene. Galectin-1 binds to beta-galactoside. It plays an important role in regulating apoptosis, cell proliferation and cell differentiation. It inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase. It is a strong inducer of T-cell apoptosis.
The report 'Galectin 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders and Respiratory which include indications Breast Cancer, Colon Cancer, Pulmonary Arterial Hypertension, Atopic Dermatitis, Autoimmune Disorders, Diabetic Nephropathy, Head And Neck Cancer Squamous Cell Carcinoma, Hypersensitivity, Kidney Fibrosis, Liver Cirrhosis, Liver Fibrosis, Metastatic Melanoma, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Portal Hypertension, Prostate Cancer, Pulmonary Fibrosis, Rheumatoid Arthritis and Sarcomas.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Galectin 1 - Pipeline Review, H1 2018'; Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Galectin-1 is a protein encoded by the LGALS1 gene. Galectin-1 binds to beta-galactoside. It plays an important role in regulating apoptosis, cell proliferation and cell differentiation. It inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase. It is a strong inducer of T-cell apoptosis.
The report 'Galectin 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders and Respiratory which include indications Breast Cancer, Colon Cancer, Pulmonary Arterial Hypertension, Atopic Dermatitis, Autoimmune Disorders, Diabetic Nephropathy, Head And Neck Cancer Squamous Cell Carcinoma, Hypersensitivity, Kidney Fibrosis, Liver Cirrhosis, Liver Fibrosis, Metastatic Melanoma, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Portal Hypertension, Prostate Cancer, Pulmonary Fibrosis, Rheumatoid Arthritis and Sarcomas.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1)
- The report reviews Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Overview
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Companies Involved in Therapeutics Development
Galectin Therapeutics Inc
GlycoMimetics Inc
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Drug Profiles
CNC-225 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNC-225 + CNC-118 + Anti-CTLA-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Activate Gal-1 for Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMCT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Galectin-1, 3, 9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Dormant Products
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Product Development Milestones
Featured News & Press Releases
Jan 25, 2018: Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
Dec 14, 2017: Galectin Therapeutics Provides Corporate Update at Annual Meeting
Dec 05, 2017: Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
Dec 04, 2017: Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017
Nov 13, 2017: Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial
Oct 20, 2017: Galectin Therapeutics to Present Clinical Data at The Liver Meeting 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
Sep 12, 2017: Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02
Jul 25, 2017: Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics
Jun 21, 2017: Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
Jun 13, 2017: Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
Jun 06, 2017: Autoimmune Disease Patent Granted to Galectin Therapeutics
Apr 25, 2017: Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
Apr 18, 2017: Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress 2017
Mar 14, 2017: GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema)
Mar 06, 2017: Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Overview
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Companies Involved in Therapeutics Development
Galectin Therapeutics Inc
GlycoMimetics Inc
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Drug Profiles
CNC-225 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNC-225 + CNC-118 + Anti-CTLA-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Activate Gal-1 for Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMCT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Galectin-1, 3, 9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Dormant Products
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Product Development Milestones
Featured News & Press Releases
Jan 25, 2018: Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
Dec 14, 2017: Galectin Therapeutics Provides Corporate Update at Annual Meeting
Dec 05, 2017: Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
Dec 04, 2017: Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017
Nov 13, 2017: Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial
Oct 20, 2017: Galectin Therapeutics to Present Clinical Data at The Liver Meeting 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
Sep 12, 2017: Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02
Jul 25, 2017: Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics
Jun 21, 2017: Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
Jun 13, 2017: Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
Jun 06, 2017: Autoimmune Disease Patent Granted to Galectin Therapeutics
Apr 25, 2017: Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
Apr 18, 2017: Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress 2017
Mar 14, 2017: GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema)
Mar 06, 2017: Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Galectin Therapeutics Inc, H1 2018
Pipeline by GlycoMimetics Inc, H1 2018
Dormant Projects, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Galectin Therapeutics Inc, H1 2018
Pipeline by GlycoMimetics Inc, H1 2018
Dormant Projects, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Galectin Therapeutics Inc
GlycoMimetics Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Galectin Therapeutics Inc
GlycoMimetics Inc
